Cargando…

PSME4 Activates mTOR Signaling and Promotes the Malignant Progression of Hepatocellular Carcinoma

BACKGROUND: As hepatocellular carcinoma (HCC) having the second-highest mortality rate globally, the early diagnosis and prognosis of HCC have always been the focus of various studies. Although PSME4 has been reported to be closely related to several malignancies, its role in HCC remains unclear. MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Sijia, Huang, Hua, Huang, Wei, Ji, Ran, Chen, Jing, Wu, Shuzhen, Wang, Liyang, Huang, Tianxin, Sheng, Yu, Yan, Haiou, Lu, Cuihua, Ma, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801729/ https://www.ncbi.nlm.nih.gov/pubmed/35115815 http://dx.doi.org/10.2147/IJGM.S344360

Ejemplares similares

PORCN promotes hepatocellular carcinogenesis via Wnt/β-catenin-dependent manner
por: Wu, Shuzhen, et al.
Publicado: (2023)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway
por: Sun, Liping, et al.
Publicado: (2021)

Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway
por: Ge, Yiqin, et al.
Publicado: (2016)

Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway
por: CAI, TIANYING, et al.
Publicado: (2023)

mTOR Regulation of Metabolism in Hematologic Malignancies
por: Mirabilii, Simone, et al.
Publicado: (2020)

Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma
por: Chen, Xinhuang, et al.
Publicado: (2017)

mTOR Signaling in Metabolism and Cancer
por: Huang, Shile
Publicado: (2020)

Epigenetic Regulation of Hepatocellular Carcinoma Progression through the mTOR Signaling Pathway
por: Guo, Mengnan, et al.
Publicado: (2021)

VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAMTOR2-mediated mTOR activation
por: Xu, Jichuan, et al.
Publicado: (2023)

Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
por: Ferrín, Gustavo, et al.
Publicado: (2020)

CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma
por: Huang, Xiu-Yan, et al.
Publicado: (2019)

Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3
por: Boulpicante, Mathilde, et al.
Publicado: (2020)

Keratin 17 upregulation promotes cell metastasis and angiogenesis in colon adenocarcinoma
por: Ji, Ran, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway
por: Pu, Zhangya, et al.
Publicado: (2022)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

Biodegradable Stent with mTOR Inhibitor-Eluting Reduces Progression of Ureteral Stricture
por: Ho, Dong-Ru, et al.
Publicado: (2021)

MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway
por: Zhang, Zhenyu, et al.
Publicado: (2018)

Hedyotis diffusa Willd. Suppresses Hepatocellular Carcinoma via Downregulating AKT/mTOR Pathways
por: Huang, Lingli, et al.
Publicado: (2021)

mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment
por: Wang, Zhuo, et al.
Publicado: (2014)

The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells
por: Cheng, Jin-Shiung, et al.
Publicado: (2019)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
por: Dittmer, Dirk P, et al.
Publicado: (2012)

Role of mTOR inhibitor in cholangiocarcinoma cell progression
por: MOOLTHIYA, PENPAK, et al.
Publicado: (2014)

USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling
por: Huang, Wen-ya, et al.
Publicado: (2022)

The Translational Regulation in mTOR Pathway
por: Yang, Miaomiao, et al.
Publicado: (2022)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway
por: Ye, Yingyi, et al.
Publicado: (2019)

Targeting mTOR for cancer therapy
por: Hua, Hui, et al.
Publicado: (2019)

mLST8 Promotes mTOR-Mediated Tumor Progression
por: Kakumoto, Kyoko, et al.
Publicado: (2015)

Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling
por: Liu, Feng, et al.
Publicado: (2016)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

mTOR Inhibitors in Advanced Biliary Tract Cancers
por: Wu, Chao-En, et al.
Publicado: (2019)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
por: Todeschini, Letizia, et al.
Publicado: (2023)

The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
por: Geissler, Edward K
Publicado: (2013)

Pml represses tumour progression through inhibition of mTOR
por: Bernardi, Rosa, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ldilqe2jg1tdm4j9r2jc20s203